NASDAQ:SEEL

Seelos Therapeutics Stock Forecast, Price & News

$3.36
+0.02 (+0.60 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.31
$3.44
50-Day Range
$3.08
$6.32
52-Week Range
$0.56
$6.60
Volume2.18 million shs
Average Volume6.75 million shs
Market Capitalization$264.03 million
P/E RatioN/A
Dividend YieldN/A
Beta3.01
30 days | 90 days | 365 days | Advanced Chart
Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Seelos Therapeutics logo

About Seelos Therapeutics

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.40 out of 5 stars

Medical Sector

726th out of 2,099 stocks

Pharmaceutical Preparations Industry

358th out of 831 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

Is Seelos Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seelos Therapeutics stock.
View analyst ratings for Seelos Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Seelos Therapeutics?

Wall Street analysts have given Seelos Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Seelos Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Seelos Therapeutics' next earnings date?

Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for Seelos Therapeutics
.

How has Seelos Therapeutics' stock price been impacted by COVID-19?

Seelos Therapeutics' stock was trading at $0.78 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SEEL stock has increased by 330.8% and is now trading at $3.36.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for SEEL?

4 brokerages have issued 12-month price targets for Seelos Therapeutics' stock. Their forecasts range from $10.00 to $15.00. On average, they anticipate Seelos Therapeutics' share price to reach $12.75 in the next year. This suggests a possible upside of 279.5% from the stock's current price.
View analysts' price targets for Seelos Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Seelos Therapeutics' key executives?

Seelos Therapeutics' management team includes the following people:
  • Dr. Raj Mehra Ph.D., Founder, Chairman, CEO, Pres & Interim CFO (Age 61, Pay $724.23k)
  • Ms. Kimberly Farrand, Sr. Director of Clinical Devel. & Operations
  • Anthony Marciano, Head of Corp. Communications
  • Gopal Krishna, Head of Manufacturing & Technical Operations
  • Tim Whitaker M.D., Chief Medical Officer

Who are some of Seelos Therapeutics' key competitors?

What other stocks do shareholders of Seelos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).

What is Seelos Therapeutics' stock symbol?

Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."

Who are Seelos Therapeutics' major shareholders?

Seelos Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (2.41%), Acuta Capital Partners LLC (2.19%), Uniplan Investment Counsel Inc. (1.95%), BlackRock Inc. (1.52%), Ikarian Capital LLC (0.91%) and Woodline Partners LP (0.91%).
View institutional ownership trends for Seelos Therapeutics
.

Which institutional investors are selling Seelos Therapeutics stock?

SEEL stock was sold by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc., Squarepoint Ops LLC, Asset Management Corp IL ADV, 1492 Capital Management LLC, and Bank of New York Mellon Corp.
View insider buying and selling activity for Seelos Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Seelos Therapeutics stock?

SEEL stock was acquired by a variety of institutional investors in the last quarter, including Mirae Asset Global Investments Co. Ltd., Acuta Capital Partners LLC, Ikarian Capital LLC, Woodline Partners LP, Millennium Management LLC, BlackRock Inc., Endurant Capital Management LP, and Jane Street Group LLC.
View insider buying and selling activity for Seelos Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Seelos Therapeutics?

Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seelos Therapeutics' stock price today?

One share of SEEL stock can currently be purchased for approximately $3.36.

How much money does Seelos Therapeutics make?

Seelos Therapeutics has a market capitalization of $264.03 million and generates $380,000.00 in revenue each year.

How many employees does Seelos Therapeutics have?

Seelos Therapeutics employs 13 workers across the globe.

What is Seelos Therapeutics' official website?

The official website for Seelos Therapeutics is www.seelostherapeutics.com.

Where are Seelos Therapeutics' headquarters?

Seelos Therapeutics is headquartered at 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022.

How can I contact Seelos Therapeutics?

Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at (646) 293-2100 or via email at [email protected]


This page was last updated on 6/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.